Cognizant Extended Technology Deal With Gilead Sciences
The five-year contract extension will integrate agentic AI and DevOps into Gilead's clinical development workflows.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you trust that outsourcing core technology and AI processes makes companies more efficient?
Cognizant has secured a five-year contract extension to manage IT infrastructure and analytics for Gilead Sciences. The partnership marks a continuation of a decade-long collaboration, now focused on deploying agentic AI tools and DevOps practices.
Why it matters
The deal aims to accelerate the execution of priority technology programs by streamlining operational workflows through advanced automation. It highlights a shift toward integrating specialized AI tools within existing life sciences infrastructure.
The agreement extends a decade-long relationship for another five years. It focuses on the application of agentic AI—autonomous software agents capable of executing tasks without human intervention—to simplify drug development processes.
The players
Cognizant
A multinational IT services firm specializing in software engineering, digital transformation, and life sciences infrastructure.
Gilead Sciences
A research-based biopharmaceutical company focused on developing and commercializing innovative medicines across three decades of operation.
The details
Cognizant will apply its life sciences domain expertise to support Gilead development and operations through specialized DevOps capabilities. DevOps is a set of practices that combines software development and IT operations to shorten the systems development lifecycle. The companies intend to utilize agentic AI to automate complex workflows and improve delivery times across Gilead's R&D pipeline.
Timeline
October 6, 2026: The five-year contract extension was announced.
The Tech Race
This agreement signals a transition from legacy infrastructure maintenance to the active deployment of autonomous AI tools within pharmaceutical R&D. It follows a broader industry race to automate drug discovery cycles by integrating agentic systems into established enterprise technology stacks.
The transition to agentic AI tools is intended to simplify internal Gilead processes, with the primary effects felt by researchers and operations teams managing clinical programs. The technology will prioritize automating repetitive tasks currently managed by legacy IT systems over the next five years.
The takeaway
This extension confirms a multi-year commitment to modernizing pharmaceutical IT with autonomous tools rather than traditional, manual analytics. Stakeholders should track future updates on operational efficiency metrics resulting from these agentic AI implementations.
Further reading
For more on the intersection of automated intelligence and pharmaceutical workflows, visit our /tech/biotech/ section.
Live Poll
Do you trust that outsourcing core technology and AI processes makes companies more efficient?
